PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Breaking down the defenses

SBKB [doi:10.1038/sbkb.2011.37]
Featured Article - September 2011
Short description: The structure of ISG15 bound to NS1B gives insight into the mechanism by which influenza B virus specifically targets humans.

An NS1B-NTR homodimer bound to two ISG15 molecules (PDB 3SDL). Reprinted with permission from Proc. Natl. Acad. Sci. USA 1 .

One of the primary methods of host defense in the battle against viruses is the interferon-induced ISG15 pathway, which inhibits the replication of several viruses, including influenza A and B viruses. ISG15 is an ubiquitin-like protein comprising two ubiquitin-like domains (UblDs) that are connected by a short linker. The ISG15 pathway closely parallels that of ubiquitin and other ubiquitin-like molecules, including activation by the E1 Ube1L, conjugation by the E2 UbcH8, and ligation by an E3 ligase, principally Herc5. This enzyme system conjugates ISG15 onto host and viral proteins.

To counter this antiviral mechanism, the influenza B virus has evolved the ability to inhibit ISG15 conjugation via its NS1 protein, NS1B. The N-terminal region of NS1B binds the N-terminal UblD of ISG15, although how this interaction leads to inhibition of the host antiviral response is not fully understood. Interestingly, the ability of NS1B to overcome the ISG15 barrier extends only to human and non-human primate ISG15; NS1B cannot bind mouse ISG15 and therefore primarily targets humans. It is known that the ISG15 linker region is important to this specificity, but whether NS1B binds the linker, or whether the linker instead regulates the conformation of ISG15 was not yet known.

To understand how NS1B enables the influenza B virus to overcome the interferon-mediated ISG15 response, Montelione, Guan, Krug, and colleagues (PSI NESG) solved the X-ray crystal structure of human ISG15 in complex with the N-terminal region of NS1B (NS1B-NTR). The complex is a heterotetramer, with the NS1B-NTR homodimer binding one ISG15 monomer on each side. Each ISG15 binding site on the NS1B-NTR dimer surface consists of residues from both monomers. The two ISG15 molecules have similar interactions with NS1B, with a few minor differences, although the biological importance of the asymmetry is not yet clear. The ISG15 linker binds the NS1B-NTR using species-specific residues in the linker, answering the question as to the role of the linker in binding NS1B. Additionally, ISG15 residues 38–51, which have several differences compared to mouse ISG15, make further contacts with NS1B-NTR, providing another level of sequence-specific recognition in this interaction.

Interestingly, the C-terminal UblD of ISG15, which is involved in conjugation, does not interact with the NS1B-NTR, and previous work has shown that NS1B-bound ISG15 can still interact with E1 and E2 conjugating enzymes. Therefore the mechanism by which NS1B inhibits ISG15 conjugation is still a mystery, although the interactions seen in the structure are crucial as mutating two key residues prevents NS1B from inhibiting ISG15 conjugation in cells. The authors propose that NS1B may function by sequestering ISG15 away from cellular interactions, an intriguing hypothesis that will undoubtedly be tested further. In the meantime, the structure presented here provides valuable insights into the mechanism of influenza B virus infection and potential sites for antiviral drug discovery efforts.

Steve Mason

References

  1. R. Guan et al. Structural basis for the sequence-specific recognition of human ISG15 by the NS1 protein of influenza B virus.
    Proc. Natl. Acad. Sci. USA (1 Aug 2011). doi:10.1073/pnas.1107032108

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health